The STOMP study found tecovirimat safe but ineffective in reducing lesion resolution or pain in adults with mild to moderate ...

The global clinical decision support system market was valued at US$ 1.2 Bn in 2022 and is projected to record a CAGR of 8.8% ...

Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models ...